STOCK TITAN

Co-Diagnostics, Inc. to CEO to Deliver Keynote Address at 2023 MarketsandMarkets Conference in London, England

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SALT LAKE CITY, March 21, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company CEO will deliver the keynote address at the 4th Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference, held March 23-24, 2023, in London, England, where the Company will also be hosting a booth.

Dwight Egan, CEO of Co-Diagnostics, will be delivering the keynote presentation on the Company's upcoming Co-Dx PCR Home™ testing platform at 9:10 am local time on March 23. Co-Dx recently announced the initiation of clinical evaluations for this at-home/POCT real-time PCR platform, which is subject to FDA review and is not currently for sale.

The MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference is expected to bring academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical and biotechnology companies together to address the challenges and future directions in diagnostic research. To learn more about the event, including registration details, please visit here.

Attendees interested in learning more about the Company and its products, including its upcoming Co-Dx PCR Home platform, are invited to visit Booth EX-4.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-ceo-to-deliver-keynote-address-at-2023-marketsandmarkets-conference-in-london-england-301775743.html

SOURCE Co-Diagnostics

Co-Diagnostics, Inc.

NASDAQ:CODX

CODX Rankings

CODX Latest News

CODX Stock Data

37.82M
30.41M
2.68%
15.77%
1.59%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SALT LAKE CITY

About CODX

co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are